中国美容医学
中國美容醫學
중국미용의학
CHINESE JOURNAL OF AESTHETIC MEDICINE
2015年
2期
25-30
,共6页
树突状细胞%细胞因子诱导的杀伤细胞%恶性黑色素瘤%化疗
樹突狀細胞%細胞因子誘導的殺傷細胞%噁性黑色素瘤%化療
수돌상세포%세포인자유도적살상세포%악성흑색소류%화료
dendritic cells(DC)%cytokine induced killer cells(CIK)%malignant melanoma%chemotherapy
目的：研究抗原负载的DC-CIK过继免疫疗法联合化疗对晚期恶性黑色素瘤的临床疗效。方法：选取郑州大学第一附属医院收治的60例晚期恶性黑色素瘤患者,28例行抗原负载的DC-CIK联合化疗（A组）,32例行单纯化疗（B组），对两组患者治疗后免疫功能、生活质量、中位生存期及无进展生存期进行比较。结果：A组治疗后外周血中CD3+, CD3+/CD4+, CD3+/CD8+, CD4+/CD8+和CD16+/CD56+细胞比值无明显变化，（＞0.05）；B组治疗后外周血中T细胞亚群比例较之前显著下降,（＜0.05）。A组行细胞回输结束后，QOL评分改善比例为57.1%，与B组改善率31.2%而言，（＜0.05）比较差异有统计学意义；A组患者的无进展生存期(月)较B组患者长（16vs9，＜0.05），A组与B组患者的总生存期，比较差异无统计学意义（＞0.05）。结论：抗原负载的DC-CIK细胞联合化疗治疗晚期恶性黑色素瘤安全有效，在提高患者免疫功能、减轻化疗不良反应、延长无进展生存期和改善患者生活质量方面具有重要作用。
目的：研究抗原負載的DC-CIK過繼免疫療法聯閤化療對晚期噁性黑色素瘤的臨床療效。方法：選取鄭州大學第一附屬醫院收治的60例晚期噁性黑色素瘤患者,28例行抗原負載的DC-CIK聯閤化療（A組）,32例行單純化療（B組），對兩組患者治療後免疫功能、生活質量、中位生存期及無進展生存期進行比較。結果：A組治療後外週血中CD3+, CD3+/CD4+, CD3+/CD8+, CD4+/CD8+和CD16+/CD56+細胞比值無明顯變化，（＞0.05）；B組治療後外週血中T細胞亞群比例較之前顯著下降,（＜0.05）。A組行細胞迴輸結束後，QOL評分改善比例為57.1%，與B組改善率31.2%而言，（＜0.05）比較差異有統計學意義；A組患者的無進展生存期(月)較B組患者長（16vs9，＜0.05），A組與B組患者的總生存期，比較差異無統計學意義（＞0.05）。結論：抗原負載的DC-CIK細胞聯閤化療治療晚期噁性黑色素瘤安全有效，在提高患者免疫功能、減輕化療不良反應、延長無進展生存期和改善患者生活質量方麵具有重要作用。
목적：연구항원부재적DC-CIK과계면역요법연합화료대만기악성흑색소류적림상료효。방법：선취정주대학제일부속의원수치적60례만기악성흑색소류환자,28례행항원부재적DC-CIK연합화료（A조）,32례행단순화료（B조），대량조환자치료후면역공능、생활질량、중위생존기급무진전생존기진행비교。결과：A조치료후외주혈중CD3+, CD3+/CD4+, CD3+/CD8+, CD4+/CD8+화CD16+/CD56+세포비치무명현변화，（＞0.05）；B조치료후외주혈중T세포아군비례교지전현저하강,（＜0.05）。A조행세포회수결속후，QOL평분개선비례위57.1%，여B조개선솔31.2%이언，（＜0.05）비교차이유통계학의의；A조환자적무진전생존기(월)교B조환자장（16vs9，＜0.05），A조여B조환자적총생존기，비교차이무통계학의의（＞0.05）。결론：항원부재적DC-CIK세포연합화료치료만기악성흑색소류안전유효，재제고환자면역공능、감경화료불량반응、연장무진전생존기화개선환자생활질량방면구유중요작용。
Objective To evaluate the therapeutic effect of dendritic cells-cytokine icduced killers cells (DC-CIK) loaded with antigen chemotherapy in the treatment of end-stage malignant melanoma (MM). Methods 60 MM patients were selected from the First Affiliated Hospital of Zhengzhou University. 28 of them were treated by DC-CIK loaded with antigen with chemotherapy (A group), and another 32 were treated by chemotherapy only (B group). The immune function, quality of life (QOL), the median progression-free survival (mPFS) and overall survival (OS) of the patients were compared between the two groups after the treatment. Results There was no obvious change of the ratio of CD3+, CD3+/CD4+, CD3+/CD8+, CD4+/CD8+and CD16+/CD56+in the peripheral blood of group A( P>0.05), while T cell subsets decreased significantly after the treatment of group B, and obviously lower than that of group A( P<0.05). 57.1% of patients in group A were improved in their quality of life, significantly higher than that of B group, which was 31.2%( P<0.05). The median progression-free survival (mPFS) of group A was longer than that of group B (16 months vs 9 months,P<0.05),while the median overall survival (OS) of the two groups had no significant difference ( P>0.05). Conclusions Treatment with DC-CIK adoptive immunotherapy combined with chemotherapy can improve effectively the immune function and reduced the side effects of chemotherapy, prolong the PFS, and improve QOL of end-stage MM patients.
